Yazar "Bayrak, Tulin" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Evaluation of cardiometabolic function with serum adropin levels in psoriasis patients
    (2021) Onder, Sevda; Bayrak, Tulin; Kaya, Yasemin; Cankaya, Soner; Ozturk, Murat
    Aim: Psoriasis is a skin disease with metabolic and cardiac comorbidities. Adropin is a peptide hormone which is thought to play a role in metabolic diseases, energy homeostasis, endothelial function and cardiac diseases in recent years. In this study, we aimed to evaluate adropin levels in psoriasis patients Materials and Methods: The study included 51 plaque psoriasis patients aged 18-65 years who had no systemic disease and had not received systemic treatment in the last three months and 37 healthy controls matched by sex, age and body mass index (BMI). Serum adropin, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglyceride (TG), fasting blood glucose (FBG), fasting serum insulin, BMI, systolic blood pressure (SBP) and diastolic blood pressure (DBP) values were recorded. Results: Serum adropin level was 73.04 ± 46.21 pg / ml in the patient group. In the control group, serum adropin level was 77.26 ± 43.69 pg / ml. Serum adropin levels were lower in the patient group, but this was not statistically significant (p = 0.667). PASI value was negatively correlated with serum adropin level. There was no correlation between serum adropin level and other variables. Insulin level, Homa-IR level, systolic and diastolic pressure were significantly higher in the patient group (p <0.05). Conclusion: In our study, although adropin levels were not significantly lower in the patient group, we concluded that this may be associated with low PASI values. The role of adropin in psoriasis vulgaris will emerge with further studies.
  • Küçük Resim
    Öğe
    Oxidant and antioxidant mechanisms in chronic kidney disease
    (2019) Karatas, Ahmet; Bayrak, Ahmet; Bayrak, Tulin; Canakci, Ebru
    Aim: The objective of this study was to evaluate the correlation of inflammation, oxidant and antioxidant biomarkers with the stages of CKD. It is well known that inflammation has an important role in CKD. While PON-1 and PAF-AH are biomarkers with antioxidant characteristics, MDA is an oxidant biomarker. Material and Methods: The participants were divided into 3 groups. Control (n=37) group, non-hemodialysis chronic kidney disease (non-HD CKD) group and hemodialysis group (n=40) . One hudred twenty-one participants were included in this cross-sectional and observational study. Serum PON-1, PAF-AH, MDA levels were measured. Results: There was a significant difference between the groups regarding the median MDRD values (p<0.001). The median MDRD value in the control, non-HD CKD and dialysis groups was 93. 36 and 7 respectively. There was also a significant difference between the groups regarding the median PON-1 value (p<0.001). The median PON-1 value in the control, predialysis and dialysis groups was 67, 63.1 and 62 respectively. There was also no significant difference between the groups regarding the median PAF-AH value (p=0.469). The median PAF-AH value in the control, predialysis and dialysis groups was 115.7, 116.95 and 117.4 respectively. There was also a significant difference between the groups regarding the median MDA value (p<0.001). Conclusion: We concluded that PON-1 and MDA might be considered as useful biomarkers in CKD patients. The correlation between PAF-AH and CKD, larger subject sizes are needed. We believe that our study will be a starting point for larger studies focused on CKD severity and antioxidant/oxidant biomarkers.
  • Küçük Resim
    Öğe
    Protective effect of ibuprofen against renal ischemia-reperfusion injury
    (2020) Karatas, Ahmet; Canakci, Ebru; Bayrak, Tulin; Benli, Erdal; Bayrak, Ahmet; Akcay Celik, Muruvvet
    Aim: Ibuprofen is an older agent, but its intravenous form is a very new drug. The aim of this study was to investigate whether intravenous form of ibuprofen has protective effect against renal ischemia reperfusion injury at two different doses such as 10-30 mg/kg.Material and Methods: Thirty-two Wistar Albino type female rats were divided into 4 groups as sham, control, IBU-10, IBU-30. In the control group, 60 minutes renal ischemia and 60 minutes reperfusion were performed. In the ibuprofen groups, at the 45th minute of ischemia, ibuprofen was administered in different doses at 10 mg/kg and 30 mg/kg through intraperitoneally. After 60 minutes of ischemia, the clamps were opened. Renal tissue and blood samples were collected from the rats at the end of the reperfusion period. Serum TAS, TOS and prolidase enzyme levels were analyzed in plasma samples. Both histopathological and biochemical evaluations were performed with kidney tissue. Results: In the groups given intravenous ibuprofen, less cellular damage was always detected. Cellular damage indicators were significantly lower in the treated rats than in the control group. Serum and tissue prolidase values were different between groups (p0.001, p0.001). Serum TAS and TOS levels were also different between groups (p=0.001, p=0.003). Serum OSI levels were also different between groups (p=0.017).Conclusion: The biochemical and pathological results obtained in our study suggest that intravenous ibuprofen, has a protective effect against kidney damage. We believe that our study will shed light on future clinical prospective studies.